Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 and Zoledronic Acid in Untreated Metastatic Renal Cell Carcinoma
NCT00582790Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2003
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in renal cell carcinoma (RCC), sponsored by University of Wisconsin–Madison. Primary endpoint: Number of Subjects With Antitumor Response. Started Aug 2003; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00582790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582790.